Literature DB >> 20941527

Prodrugs of aza nucleosides based on proton transfer reaction.

Rafik Karaman1.   

Abstract

DFT calculation results for intramolecular proton transfer reactions in Kirby's enzyme models 1-7 reveal that the reaction rate is quite responsive to geometric disposition, especially to distance between the two reactive centers, r (GM), and the angle of attack, α (the hydrogen bonding angle). Hence, the study on the systems reported herein could provide a good basis for designing aza nucleoside prodrug systems that are less hydrophilic than their parental drugs and can be used, in different dosage forms, to release the parent drug in a controlled manner. For example, based on the calculated log EM, the cleavage process for prodrug 1ProD is predicted to be about 10¹⁰ times faster than that for prodrug 7ProD and about 10⁴ times faster than prodrug 3ProD: rate( 1ProD ) > rate( 3ProD ) > rate( 7ProD ). Hence, the rate by which the prodrug releases the aza nucleoside drug can be determined according to the structural features of the linker (Kirby's enzyme model).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20941527     DOI: 10.1007/s10822-010-9389-6

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  14 in total

Review 1.  Prodrug approaches to the improved delivery of peptide drugs.

Authors:  W Wang; J Jiang; C E Ballard; B Wang
Journal:  Curr Pharm Des       Date:  1999-04       Impact factor: 3.116

2.  Relationship between rate and distance.

Authors:  Fredric M Menger; Ashley L Galloway; Djamaladdin G Musaev
Journal:  Chem Commun (Camb)       Date:  2003-09-21       Impact factor: 6.222

3.  The effective molarity (EM)--a computational approach.

Authors:  Rafik Karaman
Journal:  Bioorg Chem       Date:  2010-04-10       Impact factor: 5.275

4.  The effective molarity (EM) puzzle in proton transfer reactions.

Authors:  Rafik Karaman
Journal:  Bioorg Chem       Date:  2009-05-05       Impact factor: 5.275

5.  Efficient intramolecular general acid catalysis of nucleophilic attack on a phosphodiester.

Authors:  Anthony J Kirby; Marcelo F Lima; Davi da Silva; Christo D Roussev; Faruk Nome
Journal:  J Am Chem Soc       Date:  2006-12-27       Impact factor: 15.419

6.  Stereopopulation control. I. Rate enhancement in the lactonizations of 0-hydroxyhydrocinnamic acids.

Authors:  S Milstien; L A Cohen
Journal:  J Am Chem Soc       Date:  1972-12-27       Impact factor: 15.419

7.  Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

Authors:  Lewis R Silverman; David R McKenzie; Bercedis L Peterson; James F Holland; Jay T Backstrom; C L Beach; Richard A Larson
Journal:  J Clin Oncol       Date:  2006-08-20       Impact factor: 44.544

8.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

Authors:  Lewis R Silverman; Erin P Demakos; Bercedis L Peterson; Alice B Kornblith; Jimmie C Holland; Rosalie Odchimar-Reissig; Richard M Stone; Douglas Nelson; Bayard L Powell; Carlos M DeCastro; John Ellerton; Richard A Larson; Charles A Schiffer; James F Holland
Journal:  J Clin Oncol       Date:  2002-05-15       Impact factor: 44.544

9.  Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients.

Authors:  P Wijermans; M Lübbert; G Verhoef; A Bosly; C Ravoet; M Andre; A Ferrant
Journal:  J Clin Oncol       Date:  2000-03       Impact factor: 44.544

10.  Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.

Authors:  Hagop Kantarjian; Jean-Pierre J Issa; Craig S Rosenfeld; John M Bennett; Maher Albitar; John DiPersio; Virginia Klimek; James Slack; Carlos de Castro; Farhad Ravandi; Richard Helmer; Lanlan Shen; Stephen D Nimer; Richard Leavitt; Azra Raza; Hussain Saba
Journal:  Cancer       Date:  2006-04-15       Impact factor: 6.860

View more
  8 in total

1.  Design, synthesis and in vitro kinetic study of tranexamic acid prodrugs for the treatment of bleeding conditions.

Authors:  Rafik Karaman; Hiba Ghareeb; Khuloud Kamal Dajani; Laura Scrano; Hussein Hallak; Saleh Abu-Lafi; Gennaro Mecca; Sabino A Bufo
Journal:  J Comput Aided Mol Des       Date:  2013-07-24       Impact factor: 3.686

2.  Computationally designed prodrugs of statins based on Kirby's enzyme model.

Authors:  Rafik Karaman; Wajd Amly; Laura Scrano; Gennaro Mecca; Sabino A Bufo
Journal:  J Mol Model       Date:  2013-07-09       Impact factor: 1.810

3.  Computer-assisted design for paracetamol masking bitter taste prodrugs.

Authors:  Hatem Hejaz; Rafik Karaman; Mustafa Khamis
Journal:  J Mol Model       Date:  2011-04-15       Impact factor: 1.810

4.  Prodrugs for masking bitter taste of antibacterial drugs--a computational approach.

Authors:  Rafik Karaman
Journal:  J Mol Model       Date:  2013-02-19       Impact factor: 1.810

5.  Computer-assisted design for atenolol prodrugs for the use in aqueous formulations.

Authors:  Rafik Karaman; Khuloud Dajani; Hussein Hallak
Journal:  J Mol Model       Date:  2011-07-23       Impact factor: 1.810

6.  Prodrugs of fumarate esters for the treatment of psoriasis and multiple sclerosis--a computational approach.

Authors:  Rafik Karaman; Ghadeer Dokmak; Maryam Bader; Hussein Hallak; Mustafa Khamis; Laura Scrano; Sabino Aurelio Bufo
Journal:  J Mol Model       Date:  2012-09-02       Impact factor: 1.810

Review 7.  Enzyme Models-From Catalysis to Prodrugs.

Authors:  Zeinab Breijyeh; Rafik Karaman
Journal:  Molecules       Date:  2021-05-28       Impact factor: 4.411

8.  Design, synthesis, and in vitro kinetics study of atenolol prodrugs for the use in aqueous formulations.

Authors:  Rafik Karaman; Alaa Qtait; Khulod Khayyat Dajani; Saleh Abu Lafi
Journal:  ScientificWorldJournal       Date:  2014-01-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.